Blue Water Ventures International, Inc. BWVI
Set alert
0.00 USD 0.00 0.00%
At close · Nov 2
Day range unavailable
0.0001 52-week range 0.0153
- YTD
- +600.00%
- 1 year
- +133.33%
- Open
- —
- Prev close
- 0.0007
- Mkt cap
- 193.50K
- Vol
- 0
- Avg vol
- 8.34K
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- —
- High
- —
6M chart
Signals (13)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 26, 2026 | 1 week ago |
| SMA: Bullish | Sep 29, 2026 | 1 month ago |
| RSI: Overbought | Sep 29, 2026 | 1 month ago |
| SMA: Bullish | Sep 23, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Jul 15, 2026 | 3 months ago |
| RSI: Oversold | Jul 15, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| SMA: Bullish | Jun 16, 2026 | 4 months ago |
| RSI: Overbought | Jun 16, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 4, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
News
- Historical Regulatory Filing Deficiences Continue to Stifle Psycheceutical Biosciences
- Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space
- Dr. Neilank Jha Appointed as Executive Chairman and Chief Executive Officer of Psycheceutical Bioscience Inc.
- Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect Ketamine for PTSD
- Psycheceutical Bioscience Announces Completion of PCAOB Audit and Future Corporation Action Strategy
- First Patient Dosed in Psycheceutical's Phase I Study Exploring Topical Administration of Ketamine to Treat PTSD
- Stocks That Hit 52-Week Lows On Friday
Your note
Sign in to keep a note on BWVI — it syncs with the Stock Master app.